P3, N=672, Not yet recruiting, Aivita Biomedical, Inc. | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2028
over 1 year ago
Trial completion date • Trial primary completion date • Surgery
AV-GBM-1 was reliably manufactured. Treatment was well-tolerated, but there were numerous treatment-emergent central nervous system AEs. mPFS was longer than historical benchmarks, though no mOS improvement was noted.